Lp(a) and CVD risk & clinical tests to measure Lp(a)
This video clip is from episode #210 – Lp(a) and its impact on heart disease with Benoît Arsenault, Ph.D., originally…
Peter’s approach to managing patients with high Lp(a)
This video is a clip from episode #210 – Lp(a) and its impact on heart disease with Benoît Arsenault, Ph.D.,…
#210 – Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.
“I think we should advise people to measure Lp(a); that would be a gigantic step.” —Benoît Arsenault
When CAC Tests Are Useful and When They Are Not
This video clip is from episode #185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we…
Peter on why early prevention of atherosclerosis is critical
This video clip is from episode #185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we…
Preventing Atherosclerosis: 2 Fatal Flaws with the “10 Year Risk” Approach
This video clip is from episode #185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way…
#185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk
“If we’re still saying the same things we said 30 years ago, it could be a problem because we should have learned how to say it better, more accurately.” —Allan Sniderman
#129 – Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology
“Atherogenic lipoproteins are really the issue behind clinical atherosclerotic vascular disease. … The data has just become so overwhelming.” —Tom Dayspring